AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting
Presentations highlight new Immuno-Oncology and DNA Damage Response targets, expanding beyond checkpoint and PARP inhibitionAstraZeneca will share pioneering research and development across its successful Oncology portfolio and extensive next-generation pipeline at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, USA, 29 March to 3 April 2019. The new research will showcase AstraZeneca’s potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor, taking the DNA Damage Response (DDR) pipeline beyond PARP inhibition. Additional highlights include new